Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Document Type
Language
Clinical aspect
Year range
1.
J Alzheimers Dis ; 76(1): 27-31, 2020.
Article in English | MEDLINE | ID: covidwho-637281

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic led to an abrupt halt of many Alzheimer's disease (AD) research studies at sites spanning the world. This is especially true for studies requiring in-person contact, such as studies collecting biofluids. Since COVID-19 is likely to remain a threat for an extended period, the resumption of fluid biomarker studies requires the development and implementation of procedures that minimize the risk of in-person visits to participants, staff, and individuals handling the biofluid samples. Some issues to consider include structuring the visit workflow to minimize contacts and promote social distancing; screening and/or testing participants and staff for COVID-19; wearing masks and performing hand hygiene; and precautions for handling, storing, and analyzing biofluids. AD fluid biomarker research remains a vitally important public health priority and resuming studies requires appropriate safety procedures to protect research participants and staff.


Subject(s)
Alzheimer Disease/metabolism , Betacoronavirus , Coronavirus Infections/metabolism , Health Personnel/trends , Patient Safety , Personal Protective Equipment , Pneumonia, Viral/metabolism , Alzheimer Disease/diagnosis , Biomarkers/metabolism , Body Fluids/metabolism , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/transmission , Humans , Pandemics , Personal Protective Equipment/trends , Pneumonia, Viral/diagnosis , Pneumonia, Viral/transmission , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL
...